• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[临床活跃的垂体肿瘤]

[Clinically active pituitary tumors].

作者信息

Unger Nicole, Theodoropoulou Marily, Schilbach Katharina

机构信息

Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen, Essen, Deutschland.

Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ziemssenstr. 5, 80336, München, Deutschland.

出版信息

Inn Med (Heidelb). 2024 Jul;65(7):672-680. doi: 10.1007/s00108-024-01729-9. Epub 2024 Jun 13.

DOI:10.1007/s00108-024-01729-9
PMID:38869654
Abstract

The widespread use of diagnostic imaging has led to an increase in the incidence of pituitary tumors. The majority of incidentalomas are hormone-inactive (HI) pituitary microadenomas. The most common clinically relevant pituitary adenomas are prolactin-secreting, followed by HI, and far less common are growth hormone (GH)-, adrenocorticotropic hormone (ACTH)- and thyroid-stimulating hormone (TSH)-secreting adenomas. Pituitary adenomas are usually benign, although aggressive growth and invasion occurs in individual cases. Very rarely, they give rise to metastases and are then termed pituitary carcinomas. All pituitary tumors require endocrine testing for pituitary hormone excess. In addition to the medical history and clinical examination, laboratory diagnostics are very important. Symptoms such as irregular menstruation, loss of libido or galactorrhea often lead to the timely diagnosis of prolactinomas, and hyperprolactinemia can easily confirm the diagnosis (considering the differential diagnoses). Diagnosis is more difficult for all other hormone-secreting pituitary adenomas (acromegaly, Cushing's disease, TSHoma), as the symptoms are often non-specific (i.e., headaches, weight gain, fatigue, joint pain). Furthermore, comorbidities such as hypertension, diabetes, and depression are such widespread diseases that pituitary adenomas are rarely considered as the underlying cause. Timely diagnosis and appropriate treatment have a significant impact on morbidity, mortality, and quality of life. Therefore, the role of primary care physicians is very important for achieving an early diagnosis. In addition, patients with pituitary adenomas should always be referred to endocrinologists to ensure optimal diagnosis as well as treatment.

摘要

诊断性成像的广泛应用导致垂体肿瘤的发病率上升。大多数意外瘤是无激素活性(HI)的垂体微腺瘤。临床上最常见的相关垂体腺瘤是分泌催乳素的,其次是HI腺瘤,而分泌生长激素(GH)、促肾上腺皮质激素(ACTH)和促甲状腺激素(TSH)的腺瘤则要少见得多。垂体腺瘤通常是良性的,尽管个别病例会出现侵袭性生长和侵犯。极少数情况下,它们会发生转移,此时被称为垂体癌。所有垂体肿瘤都需要进行内分泌检测以确定是否存在垂体激素过多。除病史和临床检查外,实验室诊断非常重要。月经不规律、性欲减退或溢乳等症状往往能及时诊断出催乳素瘤,高催乳素血症也能轻松确诊(需考虑鉴别诊断)。对于所有其他分泌激素的垂体腺瘤(肢端肥大症、库欣病、促甲状腺激素瘤),诊断则更为困难,因为症状通常不具特异性(如头痛、体重增加、疲劳、关节疼痛)。此外,高血压、糖尿病和抑郁症等合并症非常普遍,垂体腺瘤很少被视为潜在病因。及时诊断和适当治疗对发病率、死亡率和生活质量有重大影响。因此,初级保健医生在实现早期诊断方面的作用非常重要。此外,垂体腺瘤患者应始终转诊至内分泌科医生处,以确保获得最佳诊断和治疗。

相似文献

1
[Clinically active pituitary tumors].[临床活跃的垂体肿瘤]
Inn Med (Heidelb). 2024 Jul;65(7):672-680. doi: 10.1007/s00108-024-01729-9. Epub 2024 Jun 13.
2
Diagnosis and treatment of pituitary adenomas.垂体腺瘤的诊断与治疗
Minerva Endocrinol. 2004 Dec;29(4):241-75.
3
Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.垂体肿瘤及其他鞍内异常肿块的诊断、治疗及预后。对353例患者的回顾性分析。
Medicine (Baltimore). 1999 Jul;78(4):236-69. doi: 10.1097/00005792-199907000-00004.
4
Clinical features and analysis in 1385 Chinese patients with pituitary adenomas.1385例中国垂体腺瘤患者的临床特征及分析
J Neurosurg Sci. 2013 Sep;57(3):267-75.
5
Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study.共分泌促甲状腺激素或泌乳素的垂体生长激素腺瘤的临床特征和治疗:一项病例对照研究。
Endocr Pract. 2024 May;30(5):441-449. doi: 10.1016/j.eprac.2024.01.013. Epub 2024 Feb 1.
6
Diagnosis and Treatment of Pituitary Adenomas: A Review.垂体腺瘤的诊断与治疗:综述
JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699.
7
Diagnosis and Management of Pituitary Adenomas: A Review.垂体腺瘤的诊断与管理:综述
JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444.
8
Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.促甲状腺激素分泌型垂体腺瘤的临床病理特征及治疗结果:一项90例的单中心研究
J Neurosurg. 2014 Dec;121(6):1462-73. doi: 10.3171/2014.7.JNS1471. Epub 2014 Sep 19.
9
The risks of overlooking the diagnosis of secreting pituitary adenomas.漏诊分泌性垂体腺瘤的风险。
Orphanet J Rare Dis. 2016 Oct 6;11(1):135. doi: 10.1186/s13023-016-0516-x.
10
Pituitary tumors and pregnancy.垂体肿瘤与妊娠
Growth Horm IGF Res. 2003 Aug;13 Suppl A:S38-44. doi: 10.1016/s1096-6374(03)00054-6.

引用本文的文献

1
Fatigue in acromegaly patients: a scoping review.肢端肥大症患者的疲劳:一项范围综述。
Front Endocrinol (Lausanne). 2025 Jul 14;16:1601661. doi: 10.3389/fendo.2025.1601661. eCollection 2025.
2
A Study in Pituitary Neuroendocrine Tumors (PitNETs): Real-Life Data Amid Baseline and Serial CT Scans.垂体神经内分泌肿瘤(PitNETs)研究:基线和系列CT扫描中的真实数据
Cancers (Basel). 2024 Oct 14;16(20):3477. doi: 10.3390/cancers16203477.
3
A Real-World Longitudinal Study in Non-Functioning Pituitary Incidentalomas: A PRECES Micro-Adenomas Sub-Analysis.

本文引用的文献

1
Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours.SF3B1 变异在催乳素细胞瘤中的流行率和临床相关性。
Eur J Endocrinol. 2023 Sep 1;189(3):372-378. doi: 10.1093/ejendo/lvad114.
2
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.催乳素分泌型垂体腺瘤的诊断和治疗:垂体学会国际共识声明。
Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5.
3
Pituitary tumours: molecular and genetic aspects.垂体瘤:分子和遗传方面。
一项关于无功能垂体意外瘤的真实世界纵向研究:PRECES微腺瘤亚分析
Diseases. 2024 Oct 2;12(10):240. doi: 10.3390/diseases12100240.
J Endocrinol. 2023 May 12;257(3). doi: 10.1530/JOE-22-0291. Print 2023 Jun 1.
4
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review.垂体癌的结局与预后因素:系统评价所得经验
Endocr Relat Cancer. 2023 Mar 31;30(5). doi: 10.1530/ERC-22-0338. Print 2023 May 1.
5
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.真实世界中免疫治疗对垂体瘤的疗效和预测因素:一项队列研究。
Eur J Endocrinol. 2022 Oct 17;187(5):685-696. doi: 10.1530/EJE-22-0647. Print 2022 Nov 1.
6
Approach to the Patient: Diagnosis of Cushing Syndrome.患者评估:库欣综合征的诊断。
J Clin Endocrinol Metab. 2022 Nov 23;107(11):3162-3174. doi: 10.1210/clinem/dgac492.
7
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.侵袭性垂体肿瘤和癌,171 例患者的特征和治疗。
Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.
8
Diagnostic workup of Cushing's syndrome.库欣综合征的诊断性检查。
J Neuroendocrinol. 2022 Aug;34(8):e13111. doi: 10.1111/jne.13111. Epub 2022 Aug 18.
9
Genetics of Cushing's disease: from the lab to clinical practice.库欣病的遗传学:从实验室到临床实践。
Pituitary. 2022 Oct;25(5):689-692. doi: 10.1007/s11102-022-01253-9. Epub 2022 Jul 19.
10
Molecular genetic testing in the management of pituitary disease.垂体疾病的分子遗传学检测。
Clin Endocrinol (Oxf). 2022 Oct;97(4):424-435. doi: 10.1111/cen.14706. Epub 2022 Mar 29.